BioStock: Cyxone announces expanded plans for Rabeximod
The Swedish biotech company Cyxone recently announced expanded plans for the development of their drug candidate Rabeximod. Four new patent applications were filed earlier this year greatly extending the potential for market exclusivity. This has led to a revision of the Rabeximod development plan. The number of possible applications and therefore the value of Rabeximod has increased significantly. The Covid-19 global pandemic continues with an imminent and immense need for better treatments where Cyxone believes that Rabeximod can make a difference. Cyxone will conduct a phase II study with Rabeximod in moderate patients with Covid-19, likely to start in the fourth quarter of 2020.
Read the full article about Cyxone at biostock.se:
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/